Incyte has started Phase 1 trials for their CALR antinbody. They have high hopes for it. Below is a quote from their Chief Science Officer on their recent quarterly call with analysts.
"And then also just to remind you completely different efforts, the CALR antibody is in the clinic now. Potentially disease modifying dash even curative in the 30% of CALR patients that are in the MF population and in the ET population. And that could be a completely different way of thinking if you can eliminate the clone and change the disease trajectory completely. And you wouldn't even be thinking then in terms of spleen and symptom response, you'd be eliminating the clone. So that's where we are with the program at the moment. Thanks."